Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study.

by Willize E van der Starre, Cees van Nieuwkoop, Uginia Thomson, Marleen S M Zijderveld-Voshart, Jan Pieter R Koopman, Tanny J K van der Reijden, Jaap T van Dissel, Esther van de Vosse
Published 2015-01-01

Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection

by Janneke Evelyne Stalenhoef, Cees van Nieuwkoop, Darius Cameron Wilson, Willize Elizabeth van der Starre, Tanny J. K. van der Reijden, Nathalie Manon Delfos, Eliane Madeleine Sophie Leyten, Ted Koster, Hans Christiaan Ablij, Johannes (Jan) Willem van ‘t Wout, Jaap Tamino van Dissel
Published 2019-02-01

Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women

by Cees van Nieuwkoop, Willize E. van der Starre, Janneke E. Stalenhoef, Anna M. van Aartrijk, Tanny J. K. van der Reijden, Albert M. Vollaard, Nathalie M. Delfos, Jan W. van ’t Wout, Jeanet W. Blom, Ida C. Spelt, Eliane M. S. Leyten, Ted Koster, Hans C. Ablij, Martha T. van der Beek, Mirjam J. Knol, Jaap T. van Dissel
Published 2017-04-01